News

Since 2007, Ingram has been a general partner of Hatteras Venture Partners, a venture capital firm that invests in early stage life science companies in the southeast US.

The study measured improvements in patients with predominantly negative symptoms of schizophrenia who received RG1678 in combination with second-generation antipsychotics. Genentech said that RG1678 was generally well tolerated

The agreement will evaluate the ability of Merrion Pharma’s patented GIPET technology to boost the bioavailablity of three of the ‘big pharma’ company’s compounds. Following the feasibility studies,

NP002 is a small molecule, orally available nicotinic receptor agonist that has been shown in preclinical studies to reduce LIDs without affecting parkinsonian symptoms. Neuraltus Pharma said the

Lanxess said the plant, with an annual capacity of 35,000 metric tons and around 200 employees, will manufacture products for industrial water treatment for the semi-conductor and pharmaceutical

Istodax is a member of a new class of cancer drugs known as histone deacetylase (HDAC) inhibitors. HDACs catalyse the removal of acetyl groups from acetylated lysine residues

Since 2006, Read has led Pfizer‘s Worldwide Biopharmaceutical Businesses which now comprises five global business units – Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets –

Cerner clients now have access to a suite of solutions and certified integration for dose tracking from compounding to delivery. The Cerner partnership will allow health systems to

The approved Oxycodone product line includes a 5mg capsule and 100mg/5ml oral solution. In addition to that Glenmark Generics and LVT have also signed a new supply and